Back to resultsIncorporating EMA and EMI Into CBT-I Using mHealth and Wearable Technologies
Primary Purpose
Insomnia
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Ecological momentary assessments/interventions with cognitive behavioural therapy for insomnia (EMA/I CBT-I)
Self-help cognitive behavioural therapy for insomnia
Sponsored by
About this trial
This is an interventional treatment trial for Insomnia focused on measuring ecological momentary intervention
Eligibility Criteria
Inclusion Criteria: Hong Kong residents at least 18 years of age; able to read Chinese and type in Chinese or English; meet the DSM-5 diagnostic criteria of insomnia disorder (difficulty initiating and/or maintaining sleep or early morning awakening, alongside clinically significant daytime impairment) based on the Brief Insomnia Questionnaire (BIQ), a diagnostic tool validated by the team; have an Insomnia Severity Index (ISI) score of at least 10 indicating clinical-level insomnia; have adequate opportunity and circumstances for sleep to occur; have an Internet-enabled mobile device (iOS or Android operating system), and are willing to provide informed consent. Exclusion Criteria: To mimic real-world settings, a less stringent set of exclusion criteria will be adopted. A Beck Depression Inventory (BDI-II) Item 9 score of at least 2 indicating a current moderate suicidal risk that requires active crisis management (referral information to professional services will be provided to those with serious suicidal risk); involvement in CBT-I in the past 6 months; a history of severe mental illness (e.g., bipolar disorder, psychotic disorder); major medical or neurocognitive disorders or side effects of medication that contribute significantly to insomnia or make participation infeasible based on the team's clinical experience; other untreated sleep disorders, including narcolepsy, obstructive sleep apnoea (OSA), and restless leg syndrome (RLS)/periodic leg movement disorder (PLMD) based on the cut-off scores (≥7 on narcolepsy; ≥15 on OSA; ≥7 on RLS/PLMD) in SLEEP-50; taking over-the-counter medication or psychotropic drugs that target insomnia within 2 weeks prior to the baseline assessment; and shift work, pregnancy, family or other commitments that interfere with regular sleep-wake patterns.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
No Intervention
Arm Label
EMA/I CBT-I group
Pure self-help CBT-I group
Care as usual
Arm Description
The participants allocated to the EMI/A CBT-I group will receive 6 weeks of smartphone-based CBT-I for approximately 1 hour per week. The EMA feature will capture the participant's momentary ratings of experiences to support therapeutic decision making. The trained therapist will prescribe EMI, provide personalised sleep advice, and adjust the treatment by dynamically adapting real-time rest-activity assessments collected using EMA and wearable devices. The participants will receive tailored moment-specific feedback from therapists when daytime symptoms are indicated. Therapists will also monitor the relationship between daytime symptoms (EMA app) and the sleep-wake pattern (wearables).
The participants in the pure self-help CBT-I group will receive 6 weeks of self-help CBT-I without EMA/I and therapist support. The CBT-I content will be identical to the content used in the EMI/A CBT-I group.
Outcomes
Primary Outcome Measures
Changes in Insomnia Severity Index (ISI)
ISI is a 7-item scale designed to evaluate perceived insomnia severity. Ratings on the 5- point Likert scale are obtained on the perceived severity of sleep-onset, sleep-maintenance, early morning awakening problems, satisfaction with current sleep pattern, interference with daily functioning, noticeable impairment attributed to the sleep problem, and level of distress caused by the sleep problem.
Secondary Outcome Measures
Changes in the Pittsburgh Sleep Quality Index (PSQI-19)
The PSQI-19 is a 19-item questionnaire used for measuring and identifying the quality of sleep. It provides a measure of global sleep quality, including sleep latency, sleep duration, habitual sleep efficiency and sleep disturbances.
Changes in 7-Day Consensus Sleep Diary
The standardized sleep diary records sleep-onset latency (SOL; min), wake after sleep onset (WASO; min), total wake time (TWT; min), total sleep time (TST; min), time in bed (TIB; min), etc.
Changes in Hospital Anxiety and Depression Scale (HADS)
A 14-item self-rating scale that measures anxiety and depression in both hospital and community settings. It is divided into an Anxiety subscale (HADS-A) and a Depression subscale (HADS-D) both containing seven intermingled items. It is for screening purposes and is not meant to be a diagnostic tool. HADS scores of 8-10, 11-14, and 15-21 represent mild, moderate, and severe anxiety and depression separately.
Changes in Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS)
The DBAS is a 16-item questionnaire used to assess sleep-related cognitions.
Changes in the Epworth Sleepiness Scale (ESS)
The ESS is an 8-item scale designed to evaluate overall daytime sleepiness.
Changes in Multidimensional Fatigue Inventory (MFI)
A 20-item self-report instrument designed to measure fatigue. Ratings on a 5-point Likert scale are obtained on the dimensions of general fatigue, physical fatigue, mental fatigue, reduced motivation and reduced activity. Scores on each subscale range from 4 to 20, with higher scores indicating greater fatigue.
Changes in Short Form (Six-Dimension) Health Survey (SF-6D)
SF-6D is a preference-based single index measure of health. A six-digit number represents each SF-6D health state, each digit denotes the level of one of six SF-6D dimensions: physical functioning, role limitation, social functioning, bodily pain, mental health, and vitality. The SF-6D index, scored from 0.0 (worst health state) to 1.0 (best health state).
Changes in Sheehan Disability Scale (SDS)
SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life.
Changes in Credibility-Expectancy Questionnaire (CEQ)
The 6-item CEQ yielded ratings of treatment credibility, acceptability/satisfaction, and expectations for success.
Changes in Insomnia Treatment Acceptability Scale (ITAS)
The 8-item Insomnia Treatment Acceptability Scale (ITAS) may examine treatment acceptability. Respondents would score each item from 0 (not at all acceptable) to 4 (very acceptable) to rate if the rationale made sense, how acceptable the treatment was for them, suitability for their sleep problem, and expected effectiveness for their sleep problem.
Full Information
NCT ID
NCT06004869
First Posted
August 9, 2023
Last Updated
August 21, 2023
Sponsor
Chinese University of Hong Kong
1. Study Identification
Unique Protocol Identification Number
NCT06004869
Brief Title
Incorporating EMA and EMI Into CBT-I Using mHealth and Wearable Technologies
Official Title
Incorporating Ecological Momentary Assessment and Intervention Into Cognitive Behavioural Therapy for Insomnia Using mHealth and Wearable Technologies: A Pilot Randomised Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 1, 2023 (Anticipated)
Primary Completion Date
September 30, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese University of Hong Kong
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This study will be a randomised controlled trial to investigate an integrated platform that incorporates ecological momentary assessments/interventions (EMA/I) into cognitive behavioural therapy for insomnia (CBT-I) using mHealth and wearable technology. The intervention is a promising prospect to address current challenges in the context of sleep medicine to provide real-time and real-world intervention with accuracy, low cost, and easy accessibility.
Detailed Description
It will be a randomised, assessor-blind controlled trial embedding both outcome and process evaluation, of the EMA/I CBT-I in conjunction with wearable sensors. The outcome evaluation will examine the treatment effect of EMA/I CBT-I compared with care-as-usual (CAU), whilst process evaluation will enhance the understanding of the causal assumptions that underpin EMA/I CBT-I to inform policy and clinical practice. 60 eligible participants will be randomly assigned to the EMA/I CBT-I group and CAU in a 1:1 allocation ratio. The participants in the EMA/I CBT-I group will receive 6 weeks of smartphone-based EMA/I CBT-I supported by a therapist. The trained therapist will prescribe EMI, provide personalised sleep advice, and adjust the treatment by dynamically adapting real-time rest-activity assessments collected using EMA and wearable devices. Assessments will be managed by an independent assessor (a research assistant) who is blind to group allocation at baseline, week 7 (1 week after treatment), and week 18 (12 weeks after treatment). The proposed study will follow the recommendations of the Consolidated Standards of Reporting Trials (CONSORT) and will be registered on ClinicalTrials.gov to ensure compliance with study design and results reporting requirements. The treatment will be provided free of charge.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia
Keywords
ecological momentary intervention
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
90 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
EMA/I CBT-I group
Arm Type
Experimental
Arm Description
The participants allocated to the EMI/A CBT-I group will receive 6 weeks of smartphone-based CBT-I for approximately 1 hour per week. The EMA feature will capture the participant's momentary ratings of experiences to support therapeutic decision making. The trained therapist will prescribe EMI, provide personalised sleep advice, and adjust the treatment by dynamically adapting real-time rest-activity assessments collected using EMA and wearable devices. The participants will receive tailored moment-specific feedback from therapists when daytime symptoms are indicated. Therapists will also monitor the relationship between daytime symptoms (EMA app) and the sleep-wake pattern (wearables).
Arm Title
Pure self-help CBT-I group
Arm Type
Active Comparator
Arm Description
The participants in the pure self-help CBT-I group will receive 6 weeks of self-help CBT-I without EMA/I and therapist support. The CBT-I content will be identical to the content used in the EMI/A CBT-I group.
Arm Title
Care as usual
Arm Type
No Intervention
Intervention Type
Behavioral
Intervention Name(s)
Ecological momentary assessments/interventions with cognitive behavioural therapy for insomnia (EMA/I CBT-I)
Intervention Description
an integrated system based on an existing multicomponent cognitive behavioural therapy for insomnia (CBT-I) and EMA app
Intervention Type
Behavioral
Intervention Name(s)
Self-help cognitive behavioural therapy for insomnia
Intervention Description
An mobile app that delivers CBT-I content.
Primary Outcome Measure Information:
Title
Changes in Insomnia Severity Index (ISI)
Description
ISI is a 7-item scale designed to evaluate perceived insomnia severity. Ratings on the 5- point Likert scale are obtained on the perceived severity of sleep-onset, sleep-maintenance, early morning awakening problems, satisfaction with current sleep pattern, interference with daily functioning, noticeable impairment attributed to the sleep problem, and level of distress caused by the sleep problem.
Time Frame
Baseline, Immediate post-treatment, 12-week follow up
Secondary Outcome Measure Information:
Title
Changes in the Pittsburgh Sleep Quality Index (PSQI-19)
Description
The PSQI-19 is a 19-item questionnaire used for measuring and identifying the quality of sleep. It provides a measure of global sleep quality, including sleep latency, sleep duration, habitual sleep efficiency and sleep disturbances.
Time Frame
Baseline, Immediate post-treatment, 12-week follow up
Title
Changes in 7-Day Consensus Sleep Diary
Description
The standardized sleep diary records sleep-onset latency (SOL; min), wake after sleep onset (WASO; min), total wake time (TWT; min), total sleep time (TST; min), time in bed (TIB; min), etc.
Time Frame
Baseline, Immediate post-treatment, 12-week follow up
Title
Changes in Hospital Anxiety and Depression Scale (HADS)
Description
A 14-item self-rating scale that measures anxiety and depression in both hospital and community settings. It is divided into an Anxiety subscale (HADS-A) and a Depression subscale (HADS-D) both containing seven intermingled items. It is for screening purposes and is not meant to be a diagnostic tool. HADS scores of 8-10, 11-14, and 15-21 represent mild, moderate, and severe anxiety and depression separately.
Time Frame
Baseline, Immediate post-treatment, 12-week follow up
Title
Changes in Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS)
Description
The DBAS is a 16-item questionnaire used to assess sleep-related cognitions.
Time Frame
Baseline, Immediate post-treatment, 12-week follow up
Title
Changes in the Epworth Sleepiness Scale (ESS)
Description
The ESS is an 8-item scale designed to evaluate overall daytime sleepiness.
Time Frame
Baseline, Immediate post-treatment, 12-week follow up
Title
Changes in Multidimensional Fatigue Inventory (MFI)
Description
A 20-item self-report instrument designed to measure fatigue. Ratings on a 5-point Likert scale are obtained on the dimensions of general fatigue, physical fatigue, mental fatigue, reduced motivation and reduced activity. Scores on each subscale range from 4 to 20, with higher scores indicating greater fatigue.
Time Frame
Baseline, Immediate post-treatment, 12-week follow up
Title
Changes in Short Form (Six-Dimension) Health Survey (SF-6D)
Description
SF-6D is a preference-based single index measure of health. A six-digit number represents each SF-6D health state, each digit denotes the level of one of six SF-6D dimensions: physical functioning, role limitation, social functioning, bodily pain, mental health, and vitality. The SF-6D index, scored from 0.0 (worst health state) to 1.0 (best health state).
Time Frame
Baseline, Immediate post-treatment, 12-week follow up
Title
Changes in Sheehan Disability Scale (SDS)
Description
SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life.
Time Frame
Baseline, Immediate post-treatment, 12-week follow up
Title
Changes in Credibility-Expectancy Questionnaire (CEQ)
Description
The 6-item CEQ yielded ratings of treatment credibility, acceptability/satisfaction, and expectations for success.
Time Frame
Baseline, Immediate post-treatment
Title
Changes in Insomnia Treatment Acceptability Scale (ITAS)
Description
The 8-item Insomnia Treatment Acceptability Scale (ITAS) may examine treatment acceptability. Respondents would score each item from 0 (not at all acceptable) to 4 (very acceptable) to rate if the rationale made sense, how acceptable the treatment was for them, suitability for their sleep problem, and expected effectiveness for their sleep problem.
Time Frame
Baseline, Immediate post-treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Hong Kong residents at least 18 years of age;
able to read Chinese and type in Chinese or English;
meet the DSM-5 diagnostic criteria of insomnia disorder (difficulty initiating and/or maintaining sleep or early morning awakening, alongside clinically significant daytime impairment) based on the Brief Insomnia Questionnaire (BIQ), a diagnostic tool validated by the team;
have an Insomnia Severity Index (ISI) score of at least 10 indicating clinical-level insomnia;
have adequate opportunity and circumstances for sleep to occur;
have an Internet-enabled mobile device (iOS or Android operating system), and
are willing to provide informed consent.
Exclusion Criteria:
To mimic real-world settings, a less stringent set of exclusion criteria will be adopted.
A Beck Depression Inventory (BDI-II) Item 9 score of at least 2 indicating a current moderate suicidal risk that requires active crisis management (referral information to professional services will be provided to those with serious suicidal risk);
involvement in CBT-I in the past 6 months;
a history of severe mental illness (e.g., bipolar disorder, psychotic disorder);
major medical or neurocognitive disorders or side effects of medication that contribute significantly to insomnia or make participation infeasible based on the team's clinical experience;
other untreated sleep disorders, including narcolepsy, obstructive sleep apnoea (OSA), and restless leg syndrome (RLS)/periodic leg movement disorder (PLMD) based on the cut-off scores (≥7 on narcolepsy; ≥15 on OSA; ≥7 on RLS/PLMD) in SLEEP-50;
taking over-the-counter medication or psychotropic drugs that target insomnia within 2 weeks prior to the baseline assessment; and
shift work, pregnancy, family or other commitments that interfere with regular sleep-wake patterns.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vincent Lam
Phone
39436575
Email
pmhlab@cuhk.edu.hk
12. IPD Sharing Statement
Learn more about this trial
Incorporating EMA and EMI Into CBT-I Using mHealth and Wearable Technologies
We'll reach out to this number within 24 hrs